Non-metastatic Prostate Cancer (nmPC) Market, Epidemiology, and Forecast - Strategic Insight until 2032

Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Non-metastatic Prostate Cancer (nmPC) - Market Insight, Epidemiology and Market Forecast -2032" report has been added to's offering.

Analysis of upcoming trends and growth opportunities in Non-metastatic Prostate Cancer (nmPC) has been detailed in a comprehensive new study, providing valuable insights into the market dynamics through 2032. The essential facets of nmPC, including diagnostics, prevalent cases, and treatment approaches, are dissected to offer an extensive understanding pivotal for market stakeholders.

Non-metastatic prostate cancer, often abbreviated as nmPC, is a localized form of cancer confined to the prostate gland and nearby lymph nodes, representing a vital phase where intervention can significantly prolong life and enhance the quality of living. Predictions enclosed within the study underscore the surge in diagnosed prevalent cases in both the United States and international markets like EU4 countries and Japan. The pathology of nmPC, combined with the detailed evaluation of recent therapeutic advancements, is poised to shape the future market trajectory.

The report delivers a closer look into high-growth sectors and illuminates trends such as the rise in utilization of advanced diagnostic methodologies like multiparametric magnetic resonance imaging (mpMRI) and the implementation of emerging treatments. Key features such as the increased acceptance of innovative drug therapies, which target the disease's progression with precision, are elucidated, framing an outlook essential for medical professionals and healthcare providers to make informed decisions.

Key Highlights:

  • Comprehensive epidemiological segmentation including historical and forecasted patient pool data.
  • Diverse treatment options such as surgery, radiation therapy, and hormonal therapy.
  • Evaluative profiles of therapies including both approved and emerging medications.
  • Country and therapy-wise market size projections up to 2032.
  • Consultative insights from Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs).

Market Insight:
Market forecasts reflect a robust growth potential with the United States leading in market share for nmPC therapies as of 2022. Whereas systemic therapy modalities are anticipated to experience the highest demand among biochemical recurrence patients. The report underscores advancements in both the surgical and drug therapy methodologies that are widely expected to redefine treatment standards of nmPC.

Among the marketed therapies, agents such as ERLEADA (apalutamide) and ORGOVYX (relugolix) have showcased efficacy in improving metastasis-free survival (MFS), addressing the unmet needs in nmPC care. Analysis draws attention to the emerging pipeline therapies offering new pathways of treatment, with potential breakthroughs anticipated, fueling optimism for stakeholders.

Market Outlook and Treatment Landscape:
The expanding market outlook shines a spotlight on novel androgen receptor inhibitors (ARIs), altering the existing paradigm for nmPC treatments. Key findings from current clinical trials bolster the evolving management recommendations, indicating a move towards more personalized, targeted therapy approaches that extend overall survival rates.

Treatment regimens involving a combination of therapies are increasingly eligible for reimbursement, signifying a shift towards more comprehensive, albeit more costly, treatments. The crucial impact of reimbursement policies and market access scenarios on the provision of state-of-the-art therapies is also presented in the report.

As the medical community forges ahead into new frontiers, this report stands as a foundational resource for anyone engaged in the diagnosis, treatment, or research of Non-metastatic Prostate Cancer, with unparalleled insight into the current state and future potential of this dynamically evolving market.

For the medical fraternity, patients, and stakeholders in the Non-metastatic Prostate Cancer healthcare sector, this report not only presents an exhaustive market landscape but also serves as a springboard for informed decision-making and strategy formulation towards improving patient outcomes and navigating market challenges through 2032.

A selection of companies mentioned in this report include

  • Candel Therapeutics

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.